AlphAIAlphAI — Financial news for AI agents
gurufocus.com$HAE

Haemonetics (HAE) Shares Jump 14% Premarket on CSL Supply Agreem

Haemonetics (HAE) shares rose 14% premarket after announcing a supply agreement with CSL Limited (CSLLY) to deploy NexSys PCS devices in U.S. plasma centers by 2027. The stock is modestly overvalued, according to GF Value, with a GF Score of 79. Insider activity shows net buying. Haemonetics has a market cap of $4.63B and a P/E ratio of 49.61x.

Original reporting
gurufocus.com
Published Oct 8, 2026, 11:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 12:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$HAE
Bullish
high confidence
Mentioned
$HAE
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$HAEBullishHigh
01

Why it matters

The partnership validates Haemonetics' technology and could drive recurring consumable sales, supporting its high GF Score.

02

Market read

A fresh supply agreement triggers a notable pre‑market rally, offering a timely trading opportunity.

03

What to watch

The agreement is non‑exclusive and rollout extends to 2027, so revenue impact may be gradual rather than immediate.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Haemonetics (HAE) supplies blood and plasma collection devices; CSL Limited is a leading plasma‑derived therapy company.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Haemonetics announced a new supply agreement with CSL Limited, driving a 14% pre‑market share jump.

Expected impact

likely continued upward pressure as investors price in higher future sales from the CSL rollout.

Evidence & confidence

The agreement is a fresh, material catalyst with a double‑digit same‑day move; no comparable news was previously reported.

Market effects

Sector

Strengthens the medical‑device/plasma‑collection sector by highlighting demand for automated plasmapheresis systems.

Regional

U.S. plasma collection market may see increased activity; CSL's U.S. centers are primary beneficiaries.

Global

Shows growing collaboration between U.S. device makers and global biotech firms, potentially prompting peers to seek similar contracts.

Counterpoint

What could challenge this read

The stock may be overvalued at a 17.7% premium to intrinsic value, risking a pull‑back after the initial hype fades.

Key entities

  • company
    Haemonetics Corp

    US‑listed medical‑device maker specializing in plasma collection systems.

  • company
    CSL Limited

    Global biotech firm expanding its U.S. plasma collection operations.

Read at source← All news

StoryHaemonetics secures CSL Plasma rollout of NexSys PCS devices across U.S. centers by end‑2027

Also covered by

6 outlets

Related articles

$HAEMedAI 8/10

Haemonetics Corp (HAE) (Q2 2027) Earnings Call Highlights: Raised Guidance and Expanded

Haemonetics Corp (HAE) reported Q2 2027 earnings, raising guidance but lowering operating margin expansion due to higher costs and investments. CEO Christopher Simon highlighted a multiyear growth opportunity with CSL, though margin contributions are expected in fiscal 2028. The company faces near-term pressures from elevated production and freight costs, with second-half margin expansion weighted toward Q4.

finance.yahoo.com
$HAEHighAI 8/10

Haemonetics Corporation Q2 2027 Earnings Call Summary

Haemonetics reported Q2 2027 plasma growth of 18%, driven by Persona PLUS adoption. CSL relationship expansion and FDA approval for PerQseal Elite were highlighted. Revenue guidance raised to 6-9%, but margin expansion lowered due to supply chain costs. Free cash flow conversion expected to exceed 80%.

finance.yahoo.com
$HAEMedAI 8/10

Haemonetics (HAE) Q2 2027 Earnings Call Transcript

Haemonetics reported Q2 2027 earnings, highlighting 6% organic growth in MedSurg and 14% in Apheresis. Key drivers include TEG 6s disposables, VASCADE products, and Persona PLUS adoption. The company raised its fiscal 2027 revenue guidance to 6%-9% organic growth and 8%-11% reported growth, citing strong first-half performance and increased visibility into customer commitments.

finance.yahoo.com
$HAEMed

Mizuho raises Haemonetics stock price target on plasma strength

Mizuho raised its price target for Haemonetics (HAE) to $165 from $140, citing 18% organic plasma growth and improved guidance. The stock has gained 151% over the past year. HAE reported Q2 earnings of $1.35 per share, beating estimates, with revenue up 9.3% YoY. BTIG also raised its target to $142. Investors note margin guidance concerns and growth spending.

investing.com
$HAEHighAI 8/10

BTIG raises Haemonetics stock price target to $142 on earnings beat

BTIG raised its price target on Haemonetics (HAE) to $142 from $130, maintaining a Buy rating. HAE's Q2 2027 revenue was $357.8M, up 9.3% YoY, beating estimates. Adjusted EPS was $1.35, exceeding expectations. All segments performed well, with Apheresis revenue at $204.8M. Adjusted gross margin increased to 61.9%. HAE raised fiscal 2027 revenue guidance but reduced adjusted EBIT margin expansion outlook.

investing.com